<DOC>
	<DOC>NCT00169585</DOC>
	<brief_summary>Multicentric, national, prospective, parallel group, controlled. The Subjects in every center will be randomized and assigned to the pharmacologic arm or the one with the biochemical monitoring</brief_summary>
	<brief_title>Levofloxacin For The Management Of Patients With Abnormal Prostate Specific Antigen (PSA)</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Prostatitis</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<criteria>Only subjects who meet all of the following criteria will be eligible to participate in this study: Male patients Age ≥ 45 years Suspected presence of prostate inflammatory foci, defined according to the following criteria: PSA ≥ 2.6 ng/mL and age ≥ 50 and &lt; 60 years (or ≥ 45 years if the patient has known family predisposition to carcinoma of the prostate) or, PSA ≥ 4.1 ng/mL and age ≥ 60 and &lt; 75 years, and normal digitorectal examination (DRE) (see section 5.2), and normal urine test with dipstick and/or microscopy carried out within 5 days of the baseline visit Patients willing and able to provide their written informed consent and to comply with study procedures. Patients with LUTS/BPH on watchful waiting or already under treatment with alphablockers or 5ARI (5alpha reductase inhibitors) for at least 6 months will also be considered eligible to participate in the study. Patients who meet any of the following criteria will not be eligible to participate in this study: Diagnosis of NIH class IIII prostatitis or clinical evidence of active acute urinary infection and/or known or suspected active bacterial infection at other sites; Diagnosis of prostate carcinoma (or PIN or ASAPS) or prior radical prostatectomy or radiotherapy or other treatments for prostate cancer; PSA &gt; 20 ng/mL; PSA values (including high values) stable over time; Start of a pharmacological therapy with 5ARI in subjects with LUTS/BPH; Permanent catheter; Prior treatment (within 4 weeks) with levofloxacin for genitalurinary infections; Known or suspected allergy to levofloxacin, including the excipients contained in the pharmacological preparation and/or confirmed tendency to photosensitivity reactions after fluoroquinolone therapy; Concomitant treatment with drugs not allowed in the study Reluctance to undergo prostate biopsy and/or risk of noncompliance; History or current evidence of alcohol or drug abuse in the last 12 months; History of any conditions that, in the opinion of the investigator, may confound the study results or create additional risks for the patient. Participation in any study of investigational or marketed drugs within 30 days before the baseline visit or during the study.</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>diagnostic-therapeutic pathway</keyword>
	<keyword>PSA</keyword>
	<keyword>DRE</keyword>
	<keyword>Levofloxacin</keyword>
</DOC>